Vitamin K2 supplementation in haemodialysis patients: a randomized dose-finding study | Zendy

Rogier Caluwé | Zendy; Stefaan J. Vandecasteele | Zendy; Bruno Van Vlem | Zendy; Cees Vermeer | Zendy; An S. De Vriese | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Vitamin K2 supplementation in haemodialysis patients: a randomized dose-finding study

Author(s) -

Rogier Caluwé,

Stefaan J. Vandecasteele,

Bruno Van Vlem,

Cees Vermeer,

An S. De Vriese

Publication year - 2013

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gft464

Subject(s) - matrix gla protein , vitamin k2 , medicine , calcification , endocrinology , vitamin , vitamin d and neurology , ectopic calcification

Haemodialysis patients suffer from accelerated vascular calcification. The vitamin K-dependent matrix Gla protein (MGP) is one of the most powerful inhibitors of vascular calcification. Haemodialysis patients have high levels of the inactive form of MGP (desphosphorylated-uncarboxylated-MGP, dp-uc-MGP) and may benefit from pharmacological doses of vitamin K2 (menaquinone) to improve the calcification inhibitory activity of MGP.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research